| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/01/2023 | 125.16% | JP Morgan | $22 → $23 | Maintains | Overweight |
| 10/20/2023 | 134.95% | B. Riley Securities | $32 → $24 | Maintains | Buy |
| 09/18/2023 | 301.37% | HC Wainwright & Co. | → $41 | Reiterates | Buy → Buy |
| 08/07/2023 | 115.37% | JP Morgan | $34 → $22 | Maintains | Overweight |
| 08/03/2023 | 17.47% | Goldman Sachs | $16 → $12 | Maintains | Neutral |
| 08/02/2023 | 213.26% | B. Riley Securities | $42 → $32 | Maintains | Buy |
| 08/02/2023 | 17.47% | Goldman Sachs | $16 → $12 | Upgrades | Sell → Neutral |
| 08/01/2023 | 213.26% | B. Riley Securities | $42 → $32 | Reiterates | Buy → Buy |
| 08/01/2023 | 301.37% | HC Wainwright & Co. | $34 → $41 | Maintains | Buy |
| 07/25/2023 | 56.63% | Goldman Sachs | $10 → $16 | Maintains | Sell |
| 07/24/2023 | 56.63% | Goldman Sachs | $10 → $16 | Maintains | Sell |
| 07/13/2023 | 311.16% | B. Riley Securities | → $42 | Reiterates | Buy → Buy |
| 06/01/2023 | 232.84% | HC Wainwright & Co. | → $34 | Reiterates | → Buy |
| 05/31/2023 | 232.84% | HC Wainwright & Co. | → $34 | Reiterates | → Buy |
| 05/02/2023 | 267.11% | Ladenburg Thalmann | $26 → $37.5 | Maintains | Buy |
| 05/01/2023 | 232.84% | HC Wainwright & Co. | $28 → $34 | Reiterates | → Buy |
| 04/17/2023 | 134.95% | Cantor Fitzgerald | → $24 | Reiterates | → Overweight |
| 04/14/2023 | 174.11% | HC Wainwright & Co. | $24 → $28 | Reiterates | → Buy |
| 03/31/2023 | 134.95% | HC Wainwright & Co. | → $24 | Reiterates | → Buy |
| 03/01/2023 | 134.95% | HC Wainwright & Co. | → $24 | Reiterates | → Buy |
| 02/07/2023 | 134.95% | Cantor Fitzgerald | $18 → $24 | Maintains | Overweight |
| 01/24/2023 | 144.74% | Evercore ISI Group | $16 → $25 | Maintains | Outperform |
| 12/30/2022 | 56.63% | Evercore ISI Group | $11 → $16 | Maintains | Outperform |
| 12/30/2022 | -41.26% | Goldman Sachs | $4 → $6 | Maintains | Sell |
| 12/30/2022 | 125.16% | B. Riley Securities | $17 → $23 | Maintains | Buy |
| 12/29/2022 | -41.26% | B of A Securities | $5 → $6 | Maintains | Underperform |
| 12/29/2022 | 134.95% | HC Wainwright & Co. | $19 → $24 | Maintains | Buy |
| 06/13/2022 | 66.42% | B. Riley Securities | $23 → $17 | Maintains | Buy |
| 05/20/2022 | -51.05% | B of A Securities | → $5 | Initiates Coverage On | → Underperform |
| 04/19/2022 | -51.05% | Goldman Sachs | $8 → $5 | Maintains | Sell |
| 04/19/2022 | 125.16% | B. Riley Securities | $35 → $23 | Maintains | Buy |
| 04/18/2022 | 86% | HC Wainwright & Co. | $68 → $19 | Maintains | Buy |
| 01/28/2022 | 565.69% | HC Wainwright & Co. | $70 → $68 | Maintains | Buy |
| 01/24/2022 | 585.27% | HC Wainwright & Co. | $75 → $70 | Maintains | Buy |
| 12/01/2021 | 252.42% | Evercore ISI Group | $55 → $36 | Maintains | Outperform |
| 12/01/2021 | 27.26% | Goldman Sachs | $26 → $13 | Maintains | Sell |
| 12/01/2021 | 634.21% | HC Wainwright & Co. | $84 → $75 | Maintains | Buy |
| 11/15/2021 | 154.53% | Goldman Sachs | $33 → $26 | Downgrades | Neutral → Sell |
| 08/02/2021 | 722.32% | HC Wainwright & Co. | $89 → $84 | Maintains | Buy |
| 04/20/2021 | 389.48% | Goldman Sachs | → $50 | Initiates Coverage On | → Neutral |
| 04/19/2021 | 771.27% | HC Wainwright & Co. | $79 → $89 | Maintains | Buy |
| 02/09/2021 | 830% | B. Riley Securities | $90 → $95 | Maintains | Buy |
| 02/08/2021 | 673.37% | HC Wainwright & Co. | $78 → $79 | Maintains | Buy |
| 02/05/2021 | 781.06% | B. Riley Securities | $67 → $90 | Maintains | Buy |
| 01/19/2021 | 663.58% | HC Wainwright & Co. | $61 → $78 | Maintains | Buy |
| 12/10/2020 | 497.16% | HC Wainwright & Co. | $38 → $61 | Maintains | Buy |
| 10/28/2020 | 369.9% | Cantor Fitzgerald | $30 → $48 | Maintains | Overweight |
| 09/01/2020 | 272% | JP Morgan | → $38 | Initiates Coverage On | → Overweight |
| 08/11/2020 | 272% | HC Wainwright & Co. | $32 → $38 | Maintains | Buy |
| 05/18/2020 | 262.21% | B. Riley Securities | $29 → $37 | Maintains | Buy |
| 05/06/2020 | 183.9% | B. Riley Securities | $25 → $29 | Maintains | Buy |
| 05/06/2020 | 242.63% | Cantor Fitzgerald | $19 → $35 | Maintains | Overweight |
| 05/05/2020 | 213.26% | HC Wainwright & Co. | $24 → $32 | Maintains | Buy |
| 01/17/2020 | 134.95% | HC Wainwright & Co. | $20 → $24 | Maintains | Buy |
| 11/14/2019 | 86% | Cantor Fitzgerald | $20 → $19 | Maintains | Overweight |
| 03/29/2019 | — | Cantor Fitzgerald | Initiates Coverage On | → Overweight |
What is the target price for TG Therapeutics (TGTX)?
The latest price target for TG Therapeutics (NASDAQ: TGTX) was reported by JP Morgan on November 1, 2023. The analyst firm set a price target for $23.00 expecting TGTX to rise to within 12 months (a possible 125.16% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for TG Therapeutics (TGTX)?
The latest analyst rating for TG Therapeutics (NASDAQ: TGTX) was provided by JP Morgan, and TG Therapeutics maintained their overweight rating.
When is the next analyst rating going to be posted or updated for TG Therapeutics (TGTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TG Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TG Therapeutics was filed on November 1, 2023 so you should expect the next rating to be made available sometime around November 1, 2024.
Is the Analyst Rating TG Therapeutics (TGTX) correct?
While ratings are subjective and will change, the latest TG Therapeutics (TGTX) rating was a maintained with a price target of $22.00 to $23.00. The current price TG Therapeutics (TGTX) is trading at is $10.22, which is out of the analyst's predicted range.